E

Evolus
D

EOLS

12.620
USD
-0.44
(-3.33%)
Market Closed
Volume
11,046
EPS
-0
Div Yield
-
P/E
-14
Market Cap
799,117,242
Related Instruments
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BDX
    BDX
    -2.040
    (-0.90%)
    225.190 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MDT
    MDT
    1.520
    (1.77%)
    86.2 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.29 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    More
News

Title: Evolus

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.